Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is established== | ==Diseases for which it is established== | ||
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
| + | **[[Clear cell renal cell carcinoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 27: | Line 28: | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
| + | [[Category:Clear cell renal cell carcinoma medications]] | ||
[[Category:Renal cell carcinoma medications]] | [[Category:Renal cell carcinoma medications]] | ||
[[Category:EMA approved in 2017]] | [[Category:EMA approved in 2017]] | ||
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
Revision as of 00:29, 7 November 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established
Patient drug information
History of changes in FDA indication
- 2021-03-10: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
History of changes in EMA indication
- 2017-08-24: Initial authorization for first line treatment of adult patients with advanced renal cell carcinoma (RCC). (Based on TIVO-1)
- 2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. (Based on TIVO-1)
Also known as
- Code name: AV-951
- Brand name: Fotivda